Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer.
dc.contributor.author | D'Amico, Anthony V | |
dc.contributor.author | Chen, Ming-Hui | |
dc.contributor.author | Crook, Juanita | |
dc.contributor.author | Armstrong, John G | |
dc.contributor.author | Malone, Shawn | |
dc.contributor.author | Steigler, Allison | |
dc.contributor.author | Dunne, Mary | |
dc.contributor.author | Kantoff, Philip W | |
dc.contributor.author | Denham, James W | |
dc.date.accessioned | 2012-05-08T11:08:38Z | |
dc.date.available | 2012-05-08T11:08:38Z | |
dc.date.issued | 2011-12-10 | |
dc.identifier.citation | Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. 2011, 29 (35):4682-7 J. Clin. Oncol. | en_GB |
dc.identifier.issn | 1527-7755 | |
dc.identifier.pmid | 22042952 | |
dc.identifier.doi | 10.1200/JCO.2011.37.0726 | |
dc.identifier.uri | http://hdl.handle.net/10147/222411 | |
dc.description.abstract | We evaluated whether the duration of androgen suppression therapy (AST) had an impact on the risk of prostate cancer-specific mortality (PCSM) in men with unfavorable-risk prostate cancer (PC) within established Gleason score (GS) categories. | |
dc.language.iso | en | en |
dc.rights | Archived with thanks to Journal of clinical oncology : official journal of the American Society of Clinical Oncology | en_GB |
dc.subject.mesh | Aged | |
dc.subject.mesh | Androgen Antagonists | |
dc.subject.mesh | Antineoplastic Agents, Hormonal | |
dc.subject.mesh | Cohort Studies | |
dc.subject.mesh | Combined Modality Therapy | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Male | |
dc.subject.mesh | Neoplasm Staging | |
dc.subject.mesh | Prognosis | |
dc.subject.mesh | Prostatic Neoplasms | |
dc.subject.mesh | Treatment Outcome | |
dc.title | Duration of short-course androgen suppression therapy and the risk of death as a result of prostate cancer. | en_GB |
dc.type | Article | en |
dc.contributor.department | Brigham and Women's Hospital, Boston, MA 02115, USA. adamico@partners.org | en_GB |
dc.identifier.journal | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | en_GB |
dc.description.province | Leinster | en |
html.description.abstract | We evaluated whether the duration of androgen suppression therapy (AST) had an impact on the risk of prostate cancer-specific mortality (PCSM) in men with unfavorable-risk prostate cancer (PC) within established Gleason score (GS) categories. |